Phenotypes associated with this allele

• Allele Symbol: Cebpb^tm1Es
• Allele Name: targeted mutation 1, Esta Sterneck
• Allele ID: MGI:3623142
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Cebpb^tm1Es/Cebpb^tm1Es Tg(KRT5-cre)5132Jlj/?	involves: 129S1/Sv * C57BL/6J * DBA/2J	MGI:3625476
cn2	Cebpa^tm1Gonz/Cebpa^tm1Gonz Cebpb^tm1Es/Cebpb^tm1Es Tg(KRT14-cre/ERT)20Efu/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1	MGI:5645076
cn3	Cebpb^tm1Es/Cebpb^tm1Es Tg(KRT14-cre/ERT)20Efu/0	involves: 129S1/Sv * C57BL/6 * CD-1	MGI:5645046

Genotype
MGI:3625476

cn1

• Allelic Composition: Cebpb^tm1Es/Cebpb^tm1Es; Tg(KRT5-cre)5132Jlj/?
• Genetic Background: involves: 129S1/Sv * C57BL/6J * DBA/2J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

decreased incidence of tumors by chemical induction ( J:107334 )

• complete resistant to DMBA/TPA-induced papillomas

integument

increased keratinocyte apoptosis ( J:107334 )

• DMBA-treated mutant mice displayed 9- to 13-fold net increase in the number of apoptotic basal keratinocytes compared to control

homeostasis/metabolism

decreased incidence of tumors by chemical induction ( J:107334 )

• complete resistant to DMBA/TPA-induced papillomas

cellular

increased keratinocyte apoptosis ( J:107334 )

• DMBA-treated mutant mice displayed 9- to 13-fold net increase in the number of apoptotic basal keratinocytes compared to control

Genotype
MGI:5645076

cn2

• Allelic Composition: Cebpa^tm1Gonz/Cebpa^tm1Gonz; Cebpb^tm1Es/Cebpb^tm1Es; Tg(KRT14-cre/ERT)20Efu/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1

cellular

abnormal keratinocyte differentiation ( J:158721 )

• 4OHT-treated mutant mice show molecular changes in K5, K14, K1, and K10 that are consistent with a defect in the basal to spinous keratinocyte transition

increased keratinocyte proliferation ( J:158721 )

• 4OHT-treated mutant mice show a significant increase in the numbers of BrdU positive S-phase cells in the IFE and ORS keratinocytes relative to controls

• a 4.7-fold increase is noted in BrdU positive basal S-phase keratinocytes

• a ~27-fold increase is noted in in BrdU positive suprabasal S-phase keratinocytes

endocrine/exocrine glands

abnormal sebaceous gland morphology ( J:158721 )

• in 4OHT-treated mutant mice, sebaceous glands contain abnormal looking sebocytes that appear undifferentiated, show reduced cytoplasmic volume, and lack clear fine vacuolation supportive of lipid accumulation

• affected glands show increased cellular density with more closely apposed nuclei and the cells are morphologically similar to reserve undifferentiated cells

abnormal male preputial gland morphology ( J:158721 )

♂ • 4OHT-treated mutant mice show marked atrophy of preputial gland lobules and reduced numbers of clear finely vacuolated sebocytes

abnormal sebocyte morphology ( J:158721 )

• in 4OHT-treated mutant mice, sebaceous glands contain abnormal looking sebocytes that appear undifferentiated

abnormal sebocyte differentiation ( J:158721 )

• 4OHT-treated mutant mice exhibit loss of morphologically distinct differentiated sebocytes in the sebaceous, Meibomian, and preputial glands

• in 4OHT-treated mutant mice, sebaceous gland lobules associated with hair follicles fail to stain with Oil Red O indicating the absence of sebum and terminally differentiated sebocytes

• sebocyte differentiation is blocked as determined by reduced expression of stearoyl-CoA desaturase and melanocortin 5 receptor, two markers of terminal sebocyte differentiation

abnormal Meibomian gland morphology ( J:158721 )

• 4OHT-treated mutant mice display hyperplasia of the Meibomian ducts

Meibomian gland atrophy ( J:158721 )

• 4OHT-treated mutant mice display atrophic Meibomian glands with greatly reduced lobule size and reduced numbers of differentiated sebocytes with clear vacuolated cytoplasm

abnormal sebaceous lipid secretion ( J:158721 )

• 4OHT-treated mutant mice exhibit lack of sebum production

integument

increased keratinocyte proliferation ( J:158721 )

• 4OHT-treated mutant mice show a significant increase in the numbers of BrdU positive S-phase cells in the IFE and ORS keratinocytes relative to controls

• a 4.7-fold increase is noted in BrdU positive basal S-phase keratinocytes

• a ~27-fold increase is noted in in BrdU positive suprabasal S-phase keratinocytes

abnormal sebaceous gland morphology ( J:158721 )

• in 4OHT-treated mutant mice, sebaceous glands contain abnormal looking sebocytes that appear undifferentiated, show reduced cytoplasmic volume, and lack clear fine vacuolation supportive of lipid accumulation

• affected glands show increased cellular density with more closely apposed nuclei and the cells are morphologically similar to reserve undifferentiated cells

abnormal male preputial gland morphology ( J:158721 )

♂ • 4OHT-treated mutant mice show marked atrophy of preputial gland lobules and reduced numbers of clear finely vacuolated sebocytes

abnormal sebocyte morphology ( J:158721 )

• in 4OHT-treated mutant mice, sebaceous glands contain abnormal looking sebocytes that appear undifferentiated

abnormal sebocyte differentiation ( J:158721 )

• 4OHT-treated mutant mice exhibit loss of morphologically distinct differentiated sebocytes in the sebaceous, Meibomian, and preputial glands

• in 4OHT-treated mutant mice, sebaceous gland lobules associated with hair follicles fail to stain with Oil Red O indicating the absence of sebum and terminally differentiated sebocytes

• sebocyte differentiation is blocked as determined by reduced expression of stearoyl-CoA desaturase and melanocortin 5 receptor, two markers of terminal sebocyte differentiation

abnormal Meibomian gland morphology ( J:158721 )

• 4OHT-treated mutant mice display hyperplasia of the Meibomian ducts

Meibomian gland atrophy ( J:158721 )

• 4OHT-treated mutant mice display atrophic Meibomian glands with greatly reduced lobule size and reduced numbers of differentiated sebocytes with clear vacuolated cytoplasm

abnormal sebaceous lipid secretion ( J:158721 )

• 4OHT-treated mutant mice exhibit lack of sebum production

abnormal hair follicle infundibulum morphology ( J:158721 )

• 4OHT-treated mutant mice display focal and regional areas of moderate to severe hyperplasia of the follicular infundibular epithelium and the infundibular outer root sheath (ORS) keratinocytes

hair follicle outer root sheath hyperplasia ( J:158721 )

• 4OHT-treated mutant mice display hyperplasia of the infundibular outer root sheath (ORS) keratinocytes

abnormal epidermal layer morphology ( J:158721 )

• 4OHT-treated mutant mice show defects in epidermal stratified squamous differentiation

abnormal keratinocyte differentiation ( J:158721 )

• 4OHT-treated mutant mice show molecular changes in K5, K14, K1, and K10 that are consistent with a defect in the basal to spinous keratinocyte transition

abnormal epidermis stratum basale morphology ( J:158721 )

• 4OHT-treated mutant mice display a dysplastic, disorganized basal layer with highly abnormal variations in cell and nucleus size

• a 4.7-fold increase is noted in BrdU positive basal S-phase keratinocytes relative to controls

hyperkeratosis ( J:158721 )

• 4OHT-treated mutant mice display a significantly thickened stratum corneum

parakeratosis ( J:158721 )

• 4OHT-treated mutant mice display low levels of parakeratosis

abnormal epidermis stratum spinosum morphology ( J:158721 )

• 4OHT-treated mutant mice display a dysplastic, disorganized spinous layer with highly abnormal variations in cell and nucleus size

• K10, an early marker of the spinous layer and of the basal to spinous transition is significantly reduced

• K1, another early marker of the spinous layer, is delayed in its expression and instead of being expressed in the layer adjacent to the basal cell layer, K1 is not expressed until ~2-3 layers of cells above the basal layers

abnormal epidermis suprabasal layer morphology ( J:158721 )

• a ~27-fold increase is noted in in BrdU positive suprabasal S-phase keratinocytes relative to controls

epidermal hyperplasia ( J:158721 )

• 4OHT-treated mutant mice display hyperplasia of the interfollicular epidemis (IFE) with a significant increase in the number of nucleated epidermal cell layers; focal areas of hyperplasia are detected as early as 4 days and become more extensive and severe at 8, 12, and 18 days after start of 4OHT treatment

• severe regional epidermal hyperplasia of the haired skin eyelid epidermis is observed

renal/urinary system

abnormal male preputial gland morphology ( J:158721 )

♂ • 4OHT-treated mutant mice show marked atrophy of preputial gland lobules and reduced numbers of clear finely vacuolated sebocytes

reproductive system

abnormal male preputial gland morphology ( J:158721 )

♂ • 4OHT-treated mutant mice show marked atrophy of preputial gland lobules and reduced numbers of clear finely vacuolated sebocytes

vision/eye

abnormal eye morphology ( J:158721 )

• 4OHT-treated mutant mice exhibit dry, swollen, and partially closed eyes

abnormal Meibomian gland morphology ( J:158721 )

• 4OHT-treated mutant mice display hyperplasia of the Meibomian ducts

Meibomian gland atrophy ( J:158721 )

• 4OHT-treated mutant mice display atrophic Meibomian glands with greatly reduced lobule size and reduced numbers of differentiated sebocytes with clear vacuolated cytoplasm

dry eyes ( J:158721 )

Genotype
MGI:5645046

cn3

• Allelic Composition: Cebpb^tm1Es/Cebpb^tm1Es; Tg(KRT14-cre/ERT)20Efu/0
• Genetic Background: involves: 129S1/Sv * C57BL/6 * CD-1

cellular

abnormal keratinocyte differentiation ( J:158721 )

• 4OHT-treated mutant mice show a modest decrease in staining intensity for keratin 10 (K10)

• however, spatial expression patterns for K5, K10, loricrin and involucrin are similar to those in controls

increased keratinocyte proliferation ( J:158721 )

• 4OHT-treated mutant mice show a significant increase in the number of BrdU positive basal keratinocytes following a 1 hour pulse relative to controls

integument

integument phenotype ( J:158721 )

N • 4OHT-treated mutant mice show no major changes in the morphology of interfollicular epidemis, outer root sheath of the hair follicle, and sebaceous glands relative to controls

abnormal keratinocyte differentiation ( J:158721 )

• 4OHT-treated mutant mice show a modest decrease in staining intensity for keratin 10 (K10)

• however, spatial expression patterns for K5, K10, loricrin and involucrin are similar to those in controls

increased keratinocyte proliferation ( J:158721 )

• 4OHT-treated mutant mice show a significant increase in the number of BrdU positive basal keratinocytes following a 1 hour pulse relative to controls

epidermal hyperplasia ( J:158721 )

• 4OHT-treated mutant mice show a significant increase in the number of nucleated cell layers relative to controls

thick epidermis ( J:158721 )

• 4OHT-treated mutant mice show a moderate increase in epidermal thickness relative to controls